UTHR United Therapeutics Corporation Stock Quote

UTHR [NASD]

Index	-	P/E	15.16	EPS (ttm)	14.44	Insider Own	0.10%	Shs Outstand	45.20M	Perf Week	14.64%
Market Cap	9.81B	Forward P/E	11.47	EPS next Y	19.09	Insider Trans	-66.11%	Shs Float	44.42M	Perf Month	17.56%
Income	687.40M	PEG	7.98	EPS next Q	4.04	Inst Own	99.60%	Short Float	2.52%	Perf Quarter	13.38%
Sales	1.77B	P/S	5.55	EPS this Y	-12.90%	Inst Trans	2.36%	Short Ratio	2.35	Perf Half Y	10.07%
Book/sh	92.40	P/B	2.37	EPS next Y	9.80%	ROA	13.50%	Target Price	227.62	Perf Year	18.18%
Cash/sh	50.61	P/C	4.33	EPS next 5Y	1.90%	ROE	17.60%	52W Range	158.38 - 218.38	Perf YTD	1.33%
Dividend	-	P/FCF	14.57	EPS past 5Y	-8.00%	ROI	9.20%	52W High	0.26%	Beta	0.60
Dividend %	-	Quick Ratio	8.50	Sales past 5Y	1.10%	Gross Margin	92.90%	52W Low	38.24%	ATR	8.15
Employees	965	Current Ratio	8.80	Sales Q/Q	21.80%	Oper. Margin	51.20%	RSI (14)	76.48	Volatility	5.97% 4.29%
Optionable	Yes	Debt/Eq	0.19	EPS Q/Q	724.60%	Profit Margin	38.90%	Rel Volume	2.05	Prev Close	210.14
Shortable	Yes	LT Debt/Eq	0.19	Earnings	May 04 BMO	Payout	0.00%	Avg Volume	475.23K	Price	218.95
Recom	1.80	SMA20	19.18%	SMA50	19.32%	SMA200	12.89%	Volume	996,060	Change	4.19%

Feb-11-22

Initiated

BTIG Research

Neutral

Jul-14-21

Upgrade

Argus

Hold → Buy

$205

Apr-26-21

Resumed

Credit Suisse

Outperform

$196

Feb-01-21

Upgrade

H.C. Wainwright

Neutral → Buy

$125 → $195

Sep-14-20

Resumed

JP Morgan

Overweight

$142

Jun-25-20

Reiterated

H.C. Wainwright

Neutral

$85 → $125

Mar-10-20

Upgrade

Jefferies

Hold → Buy

$123

Feb-27-20

Upgrade

Cowen

Market Perform → Outperform

$119 → $145

Jan-31-20

Upgrade

JP Morgan

Neutral → Overweight

$120

Dec-03-19

Initiated

BofA/Merrill

Underperform

Aug-01-19

Upgrade

Ladenburg Thalmann

Neutral → Buy

$103 → $106

Aug-01-19

Upgrade

Jefferies

Underperform → Hold

$90

Jul-01-19

Upgrade

Credit Suisse

Neutral → Outperform

$98 → $101

May-17-19

Upgrade

UBS

Sell → Neutral

$115 → $94

May-09-19

Upgrade

Credit Suisse

Underperform → Neutral

$98

Oct-12-18

Upgrade

Standpoint Research

Hold → Buy

Aug-08-18

Downgrade

Credit Suisse

Neutral → Underperform

Apr-03-18

Upgrade

Credit Suisse

Underperform → Neutral

Feb-22-18

Reiterated

Barclays

Underweight

$115 → $105

Jan-18-18

Resumed

Credit Suisse

Underperform

$118

May-24-22 03:02PM	United Therapeutics gets long-awaited FDA approval as competitor Liquidia takes stock hit American City Business Journals
02:04PM	United Therapeutics Stock Sees RS Rating Jump To 89; Earns 'Blue Dot' Investor's Business Daily
01:48PM	Top Healthcare Stocks for June 2022 Investopedia
09:40AM	Why United Therapeutics (UTHR) is a Top Value Stock for the Long-Term Zacks
06:00AM	United Therapeutics Announces FDA Approval of Tyvaso DPI Business Wire
May-11-22 06:35AM	7 Biotech Stocks With Key Catalysts for May InvestorPlace
May-10-22 02:26PM	Does United Therapeutics (NASDAQ:UTHR) Deserve A Spot On Your Watchlist? Simply Wall St.
May-05-22 11:12AM	United Therapeutics (UTHR) Q1 Earnings & Sales Beat, Stock Up Zacks
May-04-22 02:38PM	United Therapeutics reports 'best quarter' to date. Heres what comes next. American City Business Journals
07:15AM	United Therapeutics (UTHR) Q1 Earnings and Revenues Surpass Estimates Zacks
06:00AM	United Therapeutics Corporation Reports First Quarter 2022 Financial Results Business Wire
Apr-29-22 06:00AM	United Therapeutics to Feature Clinical Data Across its Commercial and Development Portfolio at the 2022 American Thoracic Society International Conference Business Wire
Apr-27-22 03:03PM	United Therapeutics (UTHR) to Report Q1 Results: Wall Street Expects Earnings Growth Zacks
06:00AM	United Therapeutics Corporation to Report First Quarter 2022 Financial Results Before the Market Opens on Wednesday, May 4, 2022 Business Wire
Apr-13-22 03:04PM	Morrisville pharma looks to raise $50M amid patent dispute with United Therapeutics American City Business Journals
Apr-06-22 06:00AM	United Therapeutics Announces the Publication of Tyvaso DPI BREEZE Clinical and Long-term Data in the Journal Pulmonary Circulation Business Wire
Mar-14-22 02:56PM	United Therapeutics' (NASDAQ:UTHR) investors will be pleased with their notable 47% return over the last three years Simply Wall St.
05:18AM	United Therapeutics (UTHR) Moves 3.1% Higher: Will This Strength Last? Zacks
Mar-10-22 08:26AM	Md. man who received pig heart developed by United Therapeutics dies American City Business Journals
Mar-08-22 06:00AM	United Therapeutics Corporation to Present at the Oppenheimer 32nd Annual Healthcare Conference Business Wire
Mar-01-22 06:00AM	United Therapeutics Corporation to Present at the Cowen 42nd Annual Health Care Conference Business Wire
Feb-25-22 11:09AM	Pacira's (PCRX) Q4 Earnings Beat Estimates, Revenues Rise Y/Y Zacks
10:45AM	United Therapeutics (UTHR) Q4 Earnings & Sales Miss, Stock Down Zacks
10:00AM	Down 14.1% in 4 Weeks, Here's Why You Should You Buy the Dip in United Therapeutics (UTHR) Zacks
12:30AM	MannKind Corporation (MNKD) Q4 2021 Earnings Call Transcript Motley Fool
Feb-24-22 07:15AM	United Therapeutics (UTHR) Misses Q4 Earnings and Revenue Estimates Zacks -13.15%
06:00AM	United Therapeutics Corporation Reports Fourth Quarter and Full Year 2021 Financial Results Business Wire
Feb-21-22 09:30AM	Is United Therapeutics (UTHR) Stock a Suitable Value Pick Now? Zacks
06:00AM	United Therapeutics Corporation to Report Fourth Quarter and Full Year 2021 Financial Results Before the Market Opens on Thursday, February 24, 2022 Business Wire
Feb-17-22 03:21PM	New zoning policies in Montgomery County aimed at laying out red carpet for biotech firms American City Business Journals
Feb-16-22 10:58AM	ImmunoGen (IMGN) Up on Licensing Deal With Lilly Worth $1.7 B Zacks
09:54AM	Corcept's (CORT) Q4 Earnings Beat Estimates, Revenues Miss Zacks
Feb-15-22 05:03PM	8 Medical Stocks to Buy According to Mitchell Blutts Consonance Capital Insider Monkey
Feb-07-22 06:38PM	Formidable Asset Management, LLC Buys Flux Power Holdings Inc, BP PLC, BHP Group, Sells Eaton ... GuruFocus.com
Feb-04-22 09:38AM	Empirical Finance, LLC Buys Apple Inc, Microsoft Corp, Tesla Inc, Sells Invesco Optimum Yield ... GuruFocus.com
Feb-03-22 05:38PM	Act Capital Management, Llc Buys Adtran Inc, Meta Platforms Inc, Vir Biotechnology Inc, Sells , ... GuruFocus.com
02:36PM	10 Biotech Stocks to Buy According to Matthew Strobecks Birchview Capital Insider Monkey
Jan-21-22 06:00AM	United Therapeutics Corporation Announces Historic Achievements in its Xenotransplantation Programs Business Wire
Jan-19-22 09:38PM	Frontier Capital Management Co Llc Buys Wolfspeed Inc, Fair Isaac Corp, The Trade Desk Inc, ... GuruFocus.com
Jan-06-22 11:24AM	Is United Therapeutics (NASDAQ:UTHR) A Risky Investment? Simply Wall St.
07:56AM	7 Pharmaceutical Stocks That Could Make You Rich InvestorPlace
Jan-03-22 12:43PM	United Therapeutics accuses Liquidia, former employee of misappropriating trade secrets American City Business Journals
Dec-30-21 07:25AM	After hitting regulatory roadblock, United Therapeutics will try again with PAH treatment American City Business Journals
06:00AM	United Therapeutics Corporation to Webcast Executive Fireside Chat Conversation With J.P. Morgan Analyst Business Wire
Dec-28-21 02:38AM	GuidePath Tactical Allocation Fund Buys Laboratory Corp of America Holdings, Alphabet Inc, The ... GuruFocus.com
Dec-27-21 05:25PM	United Therapeutics Corp Insiders are Selling; Investors Should Take Notice GuruFocus.com
Dec-23-21 10:15AM	United Therapeutics Corp (UTHR) Chairperson & CEO Martine A Rothblatt Sold $623,920 of Shares GuruFocus.com
Dec-21-21 06:15PM	United Therapeutics Corp (UTHR) Chairperson & CEO Martine A Rothblatt Sold $616,400 of Shares GuruFocus.com
Dec-19-21 05:38AM	Timothy Plan Aggressive Growth Fund Buys Palo Alto Networks Inc, Maravai LifeSciences Holdings ... GuruFocus.com
Dec-17-21 09:15PM	United Therapeutics Corp (UTHR) EVP & General Counsel Paul A Mahon Sold $1.2 million of Shares GuruFocus.com
Dec-14-21 02:57PM	10 Healthcare Stocks to Buy Now According to Billionaire Louis Bacon Insider Monkey
Dec-07-21 09:21PM	Hedge Funds Are Crazy About United Therapeutics Corporation (UTHR) Insider Monkey
Dec-04-21 02:29PM	10 Best Healthcare Stocks to Buy According to Greg Martinezs Parkman Healthcare Partners Insider Monkey
Dec-03-21 11:31AM	United Therapeutics (UTHR) Down 6% Since Last Earnings Report: Can It Rebound? Zacks
06:00AM	United Therapeutics Named by Newsweek as One of Americas Most Responsible Companies 2022 Business Wire
Nov-26-21 06:00AM	Nonprofit News: Companies, individuals can help battle food insecurity American City Business Journals
Nov-22-21 10:39AM	Has United Therapeutics Corporation's (NASDAQ:UTHR) Impressive Stock Performance Got Anything to Do With Its Fundamentals? Simply Wall St.
Nov-10-21 02:59PM	Morrisville firm gets tentative approval for hypertension treatment, but lawsuit still a hurdle American City Business Journals
Nov-08-21 10:28AM	Were Hedge Funds Right About Piling Into United Therapeutics Corporation (UTHR)? Insider Monkey
Nov-07-21 12:57PM	Dov Gertzulins DG Capital Portfolio: Top 10 Stocks Insider Monkey
Nov-04-21 09:10AM	United Therapeutics (UTHR) Q3 Earnings & Sales Beat, Stock Up Zacks
Nov-03-21 12:01PM	United Therapeutics Corporation (UTHR) Q3 2021 Earnings Call Transcript Motley Fool +5.73%
07:15AM	United Therapeutics (UTHR) Q3 Earnings and Revenues Surpass Estimates Zacks
06:00AM	United Therapeutics Corporation Reports Third Quarter 2021 Financial Results PR Newswire
Nov-01-21 06:00AM	United Therapeutics Corporation To Present At The Credit Suisse 30th Annual Healthcare Conference PR Newswire
Oct-27-21 04:25PM	3D Systems and United Therapeutics Announce Expansion of Bioprinting Program GlobeNewswire
06:00AM	United Therapeutics Corporation To Report Third Quarter 2021 Financial Results Before The Market Opens On Wednesday, November 3, 2021 PR Newswire
Oct-24-21 05:09AM	Richard Pzenas 9 New Stock Picks Insider Monkey
Oct-21-21 06:08AM	15 Biotech and Pharmaceutical Stocks to Buy According to Palo Alto Investors Insider Monkey
06:00AM	United Therapeutics Details New Data Presented at CHEST Annual Meeting 2021 PR Newswire
Oct-20-21 03:03PM	Analysts Estimate United Therapeutics (UTHR) to Report a Decline in Earnings: What to Look Out for Zacks
07:00AM	Is This Beaten Down Biotech a Bad News Buy? Motley Fool
01:28AM	United Therapeutics' (UTHR) Tyvaso DPI NDA Gets CRL From FDA (Revised) Zacks
Oct-19-21 11:18PM	Pig-to-human organ transplants a step closer after new test MarketWatch
10:29AM	United Therapeutics' (UTHR) Tyvaso DPI NDA Gets CRL From FDA Zacks
Oct-18-21 02:38PM	United Therapeutics hits speed bump in its quest for new drug approval American City Business Journals
11:42AM	MannKind's stock falls 18% after FDA says it will not approve application for hypertension drug MarketWatch
09:20AM	Why MannKind Shares Are Falling Today Benzinga
08:45AM	FDA Declines MannKind - United Therapeutics' Formulated Treprostinil For Lung Disease Benzinga
06:36AM	UPDATE 1-U.S. FDA declines to approve United-Mannkind's lung disease therapy Reuters
06:02AM	United Therapeutics, Mannkind Fall After FDA Declines to Approve Lung Drug Investing.com
06:00AM	United Therapeutics Provides an Update on the Progress of the Tyvaso DPI New Drug Application PR Newswire
Oct-15-21 08:49AM	10 Best Biotech Stocks to Buy According to Joseph Edelmans Perceptive Advisors Insider Monkey
Oct-11-21 06:00AM	United Therapeutics to Present New Data at CHEST Annual Meeting 2021 PR Newswire
Oct-05-21 01:53PM	United Therapeutics' (NASDAQ:UTHR) earnings growth rate lags the 75% return delivered to shareholders Simply Wall St.
Oct-04-21 01:44PM	Hedge Funds Are Crazy About United Therapeutics Corporation (UTHR) Insider Monkey
Oct-01-21 01:49PM	RTP's United Therapeutics converts to public benefit corporation American City Business Journals
Sep-30-21 04:30PM	United Therapeutics Converts to a Public Benefit Corporation Following Shareholder Approval PR Newswire
Sep-10-21 06:00AM	United Therapeutics Releases its Annual Corporate Responsibility Report PR Newswire
Sep-07-21 09:54AM	United Therapeutics-MannKind's Formulated Tyvaso Shows Benefit In Pulmonary Hypertension Patients Benzinga
06:00AM	United Therapeutics Presents Tyvaso DPI BREEZE Clinical Data At The European Respiratory Society International Congress 2021 PR Newswire
Sep-03-21 11:31AM	United Therapeutics (UTHR) Up 3.4% Since Last Earnings Report: Can It Continue? Zacks
Aug-25-21 06:00AM	United Therapeutics Partners with Former NFL Player Devon Still and His Daughter Leah to Launch "Braving NeuroBLASToma" in Honor of Childhood Cancer Awareness Month PR Newswire
Aug-24-21 06:00AM	United Therapeutics to Present Tyvaso DPI BREEZE Clinical Data at the European Respiratory Society International Congress 2021 PR Newswire
Aug-12-21 11:30AM	MannKind Corporation (MNKD) Q2 2021 Earnings Call Transcript Motley Fool
Aug-05-21 10:09AM	United Therapeutics (UTHR) Q2 Earnings & Sales Beat, Stock Up Zacks
Aug-04-21 05:56PM	Why United Therapeutics Blasted 14% Higher Today Motley Fool +14.08%
12:30PM	United Therapeutics Corporation (UTHR) Q2 2021 Earnings Call Transcript Motley Fool
07:15AM	United Therapeutics (UTHR) Q2 Earnings and Revenues Surpass Estimates Zacks
06:00AM	United Therapeutics Corporation Reports Second Quarter 2021 Financial Results PR Newswire

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled formulation of prostacyclin analogue treprostinil to enhance the exercise ability in PAH patients and pulmonary hypertension associated with interstitial lung disease (PH-ILD); Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. The company also engages in developing Tyvaso DPI, a dry powder inhalation form of Tyvaso; Remunity Pump, a small, lightweight, durable pump and separate controller; RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Tyvaso PERFECT and TETON studies, which are the studies of Tyvaso in patients with World Health Organization (WHO) Group 3 pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD). It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
MAHON PAUL A	EVP & GENERAL COUNSEL	May 19	Option Exercise	111.00	6,000	666,000	42,397	May 20 04:32 PM
MAHON PAUL A	EVP & GENERAL COUNSEL	May 19	Sale	183.43	6,000	1,100,593	36,397	May 20 04:32 PM
PATUSKY CHRISTOPHER	Director	May 17	Option Exercise	63.90	2,000	127,800	3,680	May 18 04:30 PM
MAHON PAUL A	EVP & GENERAL COUNSEL	May 05	Option Exercise	111.00	6,000	666,000	42,397	May 06 04:30 PM
DWEK RAYMOND	Director	May 05	Option Exercise	48.11	2,000	96,220	2,000	May 06 04:30 PM
MAHON PAUL A	EVP & GENERAL COUNSEL	May 05	Sale	190.65	6,000	1,143,894	36,397	May 06 04:30 PM
DWEK RAYMOND	Director	Apr 28	Option Exercise	48.11	2,000	96,220	2,000	Apr 29 04:30 PM
MAHON PAUL A	EVP & GENERAL COUNSEL	Apr 21	Option Exercise	111.00	6,000	666,000	42,487	Apr 22 04:30 PM
DWEK RAYMOND	Director	Apr 21	Option Exercise	48.11	2,000	96,220	2,000	Apr 22 04:30 PM
MAHON PAUL A	EVP & GENERAL COUNSEL	Apr 21	Sale	189.18	6,000	1,135,078	36,397	Apr 22 04:30 PM
DWEK RAYMOND	Director	Apr 14	Option Exercise	48.11	2,000	96,220	2,000	Apr 15 04:30 PM
MAHON PAUL A	EVP & GENERAL COUNSEL	Apr 07	Option Exercise	111.00	6,000	666,000	42,487	Apr 08 04:30 PM
PATUSKY CHRISTOPHER	Director	Apr 07	Option Exercise	63.90	2,000	127,800	3,680	Apr 08 04:30 PM
DWEK RAYMOND	Director	Apr 07	Option Exercise	48.11	2,000	96,220	2,000	Apr 08 04:30 PM
MAHON PAUL A	EVP & GENERAL COUNSEL	Apr 07	Sale	185.52	6,000	1,113,095	36,487	Apr 08 04:30 PM
Thompson Tommy G	Director	Mar 29	Option Exercise	48.11	1,500	72,165	8,020	Mar 30 04:30 PM
MAHON PAUL A	EVP & GENERAL COUNSEL	Mar 17	Option Exercise	111.00	6,000	666,000	42,487	Mar 18 04:30 PM
Thompson Tommy G	Director	Mar 17	Option Exercise	48.11	1,509	72,598	8,029	Mar 18 04:36 PM
MAHON PAUL A	EVP & GENERAL COUNSEL	Mar 17	Sale	182.42	6,000	1,094,501	36,487	Mar 18 04:30 PM
Thompson Tommy G	Director	Mar 16	Option Exercise	48.11	1,500	72,165	8,020	Mar 18 04:36 PM
Thompson Tommy G	Director	Mar 15	Option Exercise	48.11	1,500	72,165	8,020	Mar 16 04:35 PM
PATUSKY CHRISTOPHER	Director	Mar 15	Option Exercise	88.03	2,000	176,060	3,680	Mar 16 04:35 PM
Thompson Tommy G	Director	Mar 10	Option Exercise	48.11	1,000	48,110	7,520	Mar 11 04:35 PM
MAHON PAUL A	EVP & GENERAL COUNSEL	Mar 03	Option Exercise	111.00	6,000	666,000	42,369	Mar 04 04:35 PM
Thompson Tommy G	Director	Mar 03	Option Exercise	48.11	1,500	72,165	8,020	Mar 04 04:33 PM
MAHON PAUL A	EVP & GENERAL COUNSEL	Mar 03	Sale	174.12	6,000	1,044,715	36,369	Mar 04 04:35 PM
MAHON PAUL A	EVP & GENERAL COUNSEL	Feb 17	Option Exercise	111.00	6,000	666,000	36,369	Feb 18 04:30 PM
MAHON PAUL A	EVP & GENERAL COUNSEL	Feb 17	Sale	202.17	6,000	1,213,024	30,369	Feb 18 04:30 PM
MAHON PAUL A	EVP & General Counsel	Feb 03	Option Exercise	111.00	6,000	666,000	36,369	Feb 04 04:30 PM
MAHON PAUL A	EVP & General Counsel	Feb 03	Sale	200.10	6,000	1,200,616	30,369	Feb 04 04:30 PM
MAHON PAUL A	EVP & General Counsel	Jan 20	Option Exercise	111.00	6,000	666,000	36,369	Jan 21 04:31 PM
MAHON PAUL A	EVP & General Counsel	Jan 20	Sale	205.57	6,000	1,233,440	30,369	Jan 21 04:31 PM
MAHON PAUL A	EVP & General Counsel	Jan 06	Sale	192.46	6,000	1,154,787	30,369	Jan 06 05:08 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Dec 29	Option Exercise	53.42	3,082	164,640	3,212	Dec 29 04:31 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Dec 29	Sale	212.49	3,082	654,894	130	Dec 29 04:31 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Dec 27	Option Exercise	53.42	3,082	164,640	3,212	Dec 27 04:48 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Dec 27	Sale	213.31	3,082	657,421	130	Dec 27 04:48 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Dec 22	Option Exercise	53.42	3,082	164,640	3,212	Dec 22 05:45 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Dec 22	Sale	202.44	3,082	623,920	130	Dec 22 05:45 PM
BENKOWITZ MICHAEL	President and COO	Dec 21	Option Exercise	61.06	2,400	146,544	4,635	Dec 22 04:32 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Dec 20	Option Exercise	53.42	3,082	164,640	3,212	Dec 21 04:47 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Dec 20	Sale	200.00	3,082	616,400	130	Dec 21 04:47 PM
MAHON PAUL A	EVP & General Counsel	Dec 16	Option Exercise	111.00	6,000	666,000	42,369	Dec 17 04:32 PM
BENKOWITZ MICHAEL	President and COO	Dec 16	Option Exercise	61.06	4,000	244,240	6,235	Dec 17 04:30 PM
MAHON PAUL A	EVP & General Counsel	Dec 16	Sale	195.53	6,000	1,173,171	36,369	Dec 17 04:32 PM
BENKOWITZ MICHAEL	President and COO	Dec 14	Option Exercise	61.06	4,000	244,240	6,235	Dec 15 04:32 PM
BENKOWITZ MICHAEL	President and COO	Dec 07	Option Exercise	61.06	4,000	244,240	6,235	Dec 08 05:02 PM
MAHON PAUL A	EVP & General Counsel	Dec 02	Option Exercise	111.00	6,000	666,000	42,369	Dec 02 04:30 PM
MAHON PAUL A	EVP & General Counsel	Dec 02	Sale	189.36	6,000	1,136,140	36,369	Dec 02 04:30 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Nov 24	Option Exercise	53.42	3,083	164,694	3,213	Nov 29 04:30 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Nov 24	Sale	200.64	3,083	618,573	130	Nov 29 04:30 PM
BENKOWITZ MICHAEL	President and COO	Nov 23	Option Exercise	61.06	4,000	244,240	6,235	Nov 24 04:30 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Nov 22	Option Exercise	53.42	3,083	164,694	3,213	Nov 24 04:31 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Nov 22	Sale	200.42	3,083	617,895	130	Nov 24 04:31 PM
MAHON PAUL A	EVP & General Counsel	Nov 18	Option Exercise	111.00	6,000	666,000	42,369	Nov 18 04:47 PM
BENKOWITZ MICHAEL	President and COO	Nov 18	Option Exercise	53.83	4,000	215,320	6,235	Nov 19 04:57 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Nov 17	Option Exercise	53.42	3,083	164,694	3,213	Nov 17 05:41 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Nov 17	Sale	201.90	3,083	622,458	130	Nov 17 05:41 PM
BENKOWITZ MICHAEL	President and COO	Nov 16	Option Exercise	53.83	4,000	215,320	6,235	Nov 17 05:40 PM
ROTHBLATT MARTINE A	Chairman & CEO	Nov 15	Option Exercise	53.42	3,083	164,694	3,213	Nov 15 04:35 PM
ROTHBLATT MARTINE A	Chairman & CEO	Nov 15	Sale	203.45	3,083	627,236	130	Nov 15 04:35 PM
PATUSKY CHRISTOPHER	Director	Nov 11	Option Exercise	63.90	2,000	127,800	3,680	Nov 12 04:35 PM
BENKOWITZ MICHAEL	President and COO	Nov 11	Option Exercise	53.83	4,000	215,320	6,235	Nov 12 04:33 PM
ROTHBLATT MARTINE A	Chairman & CEO	Nov 10	Option Exercise	53.42	3,083	164,694	3,213	Nov 10 04:33 PM
ROTHBLATT MARTINE A	Chairman & CEO	Nov 10	Sale	200.00	3,083	616,600	130	Nov 10 04:33 PM
BENKOWITZ MICHAEL	President and COO	Nov 09	Option Exercise	53.83	4,000	215,320	6,235	Nov 10 04:34 PM
ROTHBLATT MARTINE A	Chairman & CEO	Nov 08	Option Exercise	53.42	3,083	164,694	3,213	Nov 08 04:32 PM
DWEK RAYMOND	Director	Nov 08	Option Exercise	48.11	3,000	144,330	3,000	Nov 08 06:51 PM
ROTHBLATT MARTINE A	Chairman & CEO	Nov 08	Sale	200.94	3,083	619,498	130	Nov 08 04:32 PM
PATUSKY CHRISTOPHER	Director	Nov 08	Sale	200.16	2,300	460,368	1,680	Nov 08 04:30 PM
MAHON PAUL A	EVP & General Counsel	Nov 04	Option Exercise	111.00	6,000	666,000	42,369	Nov 04 04:31 PM
ROTHBLATT MARTINE A	Chairman & CEO	Nov 04	Option Exercise	53.42	3,083	164,694	3,213	Nov 05 04:33 PM
BENKOWITZ MICHAEL	President and COO	Nov 04	Option Exercise	53.83	4,000	215,320	6,235	Nov 05 04:31 PM
ROTHBLATT MARTINE A	Chairman & CEO	Nov 04	Sale	200.00	3,083	616,600	130	Nov 05 04:33 PM
MAHON PAUL A	EVP & General Counsel	Nov 04	Sale	201.19	6,000	1,207,153	36,369	Nov 04 04:31 PM
BENKOWITZ MICHAEL	President and COO	Nov 02	Option Exercise	53.83	4,000	215,320	6,235	Nov 03 04:37 PM
BENKOWITZ MICHAEL	President and COO	Oct 28	Option Exercise	53.83	4,000	215,320	6,235	Oct 29 04:31 PM
BENKOWITZ MICHAEL	President and COO	Oct 26	Option Exercise	53.83	4,000	215,320	6,235	Oct 27 04:32 PM
BENKOWITZ MICHAEL	President and COO	Oct 21	Option Exercise	53.83	4,000	215,320	6,235	Oct 22 04:30 PM
MAHON PAUL A	EVP & General Counsel	Oct 21	Option Exercise	111.00	6,000	666,000	42,369	Oct 21 04:30 PM
MAHON PAUL A	EVP & General Counsel	Oct 21	Sale	190.18	6,000	1,141,082	36,369	Oct 21 04:30 PM
BENKOWITZ MICHAEL	President and COO	Oct 07	Option Exercise	53.83	4,000	215,320	6,235	Oct 08 05:08 PM
MAHON PAUL A	EVP & General Counsel	Oct 07	Option Exercise	111.00	6,000	666,000	42,369	Oct 07 04:31 PM
MAHON PAUL A	EVP & General Counsel	Oct 07	Sale	190.52	6,000	1,143,144	36,369	Oct 07 04:31 PM
BENKOWITZ MICHAEL	President and COO	Sep 23	Option Exercise	53.83	4,000	215,320	6,235	Sep 24 04:31 PM
BENKOWITZ MICHAEL	President and COO	Sep 21	Option Exercise	53.83	4,000	215,320	6,235	Sep 22 04:37 PM
BENKOWITZ MICHAEL	President and COO	Sep 16	Option Exercise	53.83	4,000	215,320	6,235	Sep 17 04:39 PM
MAHON PAUL A	EVP & General Counsel	Sep 16	Option Exercise	111.00	6,000	666,000	42,369	Sep 16 04:31 PM
MAHON PAUL A	EVP & General Counsel	Sep 16	Sale	204.08	6,000	1,224,467	36,369	Sep 16 04:31 PM
BENKOWITZ MICHAEL	President and COO	Sep 14	Option Exercise	53.83	4,000	215,320	6,235	Sep 15 04:33 PM
BENKOWITZ MICHAEL	President and COO	Sep 09	Option Exercise	53.83	4,000	215,320	6,235	Sep 10 05:39 PM
BENKOWITZ MICHAEL	President and COO	Sep 07	Option Exercise	53.83	4,000	215,320	6,235	Sep 08 06:19 PM
BENKOWITZ MICHAEL	President and COO	Sep 02	Option Exercise	53.83	4,000	215,320	6,235	Sep 02 05:24 PM
MAHON PAUL A	EVP & General Counsel	Sep 02	Option Exercise	111.00	6,000	666,000	42,369	Sep 02 05:25 PM
MAHON PAUL A	EVP & General Counsel	Sep 02	Sale	210.94	6,000	1,265,650	36,369	Sep 02 05:25 PM
BENKOWITZ MICHAEL	President and COO	Aug 31	Option Exercise	53.83	4,000	215,320	6,235	Sep 01 04:31 PM
BENKOWITZ MICHAEL	President and COO	Aug 26	Option Exercise	53.83	4,000	215,320	6,235	Aug 27 04:32 PM
BENKOWITZ MICHAEL	President and COO	Aug 24	Option Exercise	53.83	4,000	215,320	6,235	Aug 24 06:27 PM
MAHON PAUL A	EVP & General Counsel	Aug 23	Option Exercise	111.00	6,000	666,000	42,369	Aug 24 04:33 PM
MAHON PAUL A	EVP & General Counsel	Aug 23	Sale	205.82	6,000	1,234,901	36,369	Aug 24 04:33 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience